




# Unveiling the Oncology Journey: Highlighting cutting-edge capabilities



Cerba Research has conducted nearly 200 oncology trials within the last 5 years alone. Its experience extends to both solid and liquid tumors and includes specialized assays such as next-generation sequencing (NGS), flow cytometry (FCM), immunohistochemistry (IHC), and NanoString®.

Notably, Cerba Research has played a pivotal role in the approval of 24 innovative oncology drugs for indications like multiple myeloma and breast cancer, as well as 3 cell and gene therapies.

## Our Oncology Highlights

29,400+ Patients screened


23,300+ Patients randomized

~200 Oncology trials since 2018


~75% Trials include specialty testing

24 Approved oncology medications

## Oncology Overview




## Clinical Trial Phases Overview





# Sponsor Type

Oncology clinical trials experience in 2023 – facts and figures



## Indications By Solid Tumor\*



2%

Glioblastoma



4%

Pancreatic Cancer



4%

Ovarian Cancer



6%

Colorectal Cancer



7%

Non-Small Cell Lung Cancer



9%

Prostate Cancer



14%

Breast Cancer



18%

Bundled Rare Tumor Types



38%

Solid Tumors\*\*



# Sponsor Type



1% Other/NPO



18% Large pharma



9% Small-Midsize Pharma



72% Biotech/  
Biopharma

~200 Oncology trials since 2018

## OncoSign 600+ (638 Genes)

More Panels Available On Demand

Our comprehensive solid tumor profiling assay, which is CE-marked, supports identification of DNA and RNA variants implicated in various solid tumor types. This comprehensive tumor genomic profiling assay evaluates 638 genes, including 20 fusions, for multiple variant types, including TMB, MSI & HRD. It covers mutations with established, emerging & exploratory value across lung, ovarian, breast, colon, melanoma, bladder, GIST and more. It is performed on FFPE with 2 tubes containing 5 curls of 5 u thickness.



### Turnaround Time

- 15 Days



### Services Included

- DNA/RNA extraction
- QC
- Library prep
- Sequencing
- Alignment
- Data analysis, including SNVs, MNVs, INDELS, CNVs, gene fusions, etc
- TMB, MSI, HRD



### Deliverables

- Data analysis reports





## A Cerba Research capabilities snapshot for your Oncology Trial

### Cell

- FCM, Cytex Aurora immunophenotyping (including intra-cell markers)
- Receptor occupancy
- MRD detection
- CAR T cell enumeration
- CAR T cell phenotyping
- Intracellular cytokine detection
- PBMC isolation
- BMNC isolation
- Optical genome mapping, our next generation cytogenetic
- PK/ADA/Nab

### Tissue

- Multiplex/simplex IHC
- 250+ biomarkers/protocols
- Full histopath service
- Halo®, Visiopharm®, AlForia®
- Board certified pathologists
- Large biobank
- Strong immuno-oncology simplex & multiplex panels
- Spatial analysis of the tumor microenvironment
- NanoString®, FISH, ISH

### DNA/RNA

- NGS, oncopanels, broad panels, custom panels
- RNA seq
- Single-gene
- ctDNA-based panels
- ddPCR, qPCR
- Whole exome/whole genome
- HLA typing
- TCR/BCR seq
- NanoString®
- SNP-array
- DNA/RNA extraction
- Streck cell-free DNA BCT®
- PaxGene®, Qiamp kits

### Protein

- Multiplex cytokine profiling (37-plex)
- 50+ ligand binding assays
- ELISA
- ELLA
- MSD
- ELISpot
- PK/ADA/Nab

### Routine/Safety

- Coagulation
- Hematology
- Biochemistry
- Urinalysis
- Pregnancy test
- COVID test
- Serology
- Thyroid function

## Acronyms

ADA: Antibody-drug antibody, ADC: Antibody-drug conjugate, BCR: B cell receptor, BMNC: Bone marrow mononuclear cells, CAR T: Chimeric antigen receptor T cell, CGT: Cell and gene therapy, CNV: Copy number variation, ddPCR: Droplet digital polymerase chain reaction, DNA: Deoxyribonucleic acid, ELISA: Enzyme-linked immunosorbent assay, FCM: Flow cytometry, FFPE: Formalin-fixed paraffin-embedded, FISH: Fluorescence in situ hybridization, GIST: Gastrointestinal stromal tumor, HLA: Human leukocyte antigens, HRD: Homologous recombination deficiency, FIH: First in human, IHC: Immunohistochemistry, INDEL: Insertion-deletion, ISH: In situ hybridization, mAb: Monoclonal antibodies, MRD: Minimal residual disease, MSD: Mesoscale discovery, MSI: Microsatellite instability, Nab: Neutralizing antibody, NC: Not confirmed, PBMC: Peripheral blood mononuclear cells, PK: Pharmacokinetics, QC: Quality control, qPCR: Quantitative polymerase chain reaction, RNA: Ribonucleic acid, SNP: Single nucleotide polymorphism, SNV: Single nucleotide variant, TCR: T cell receptor, TMB: Tumor mutational burden.

